ARTICLE | Clinical News
Dacogen decitabine regulatory update
July 25, 2011 7:00 AM UTC
Johnson & Johnson disclosed in its 2Q11 earnings that it submitted an MAA to EMA for Dacogen decitabine to treat acute myelogenous leukemia (AML). An sNDA for the hypomethylating agent is under review...